Staphylococcus aureus with reduced susceptibility to vancomycin in healthcare settings

Journal of Preventive Medicine and Hygiene

Volumn 55, Issue , 2014, Pages 137-144

  Spagnolo, A M ^a   Orlando, P ^a   Panatto, D ^a   Amicizia, D ^a   Perdelli, F ^a   Cristina, M L ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

GISA; Glycopeptide; H GISA; MRSA; Staphylococcus aureus; Vancomycin

Indexed keywords

BACTERIAL PROTEIN; DAPTOMYCIN; GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTACT EXAMINATION; CROSS RESISTANCE; DISEASE SURVEILLANCE; ENVIRONMENTAL SANITATION; GLYCOPEPTIDE INTERMEDIATE RESISTANT STAPHYLOCOCCUS AUREUS; HAND WASHING; HEALTH CARE; HUMAN; INFECTION CONTROL; INFECTION CONTROL PRACTITIONER; INFECTION PREVENTION; INTENSIVE CARE UNIT; MEDICAL INFORMATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NONHUMAN; PENICILLIN RESISTANCE; PREVALENCE; REVIEW; SCREENING TEST; STAFF TRAINING; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; ANTIBIOTIC RESISTANCE; CROSS INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; PHYSIOLOGY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; DAPTOMYCIN; HAND HYGIENE; HUMANS; INFECTION CONTROL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84938686004     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Acar JF, Kaplan EL, O'Brien TF. Monitoring and management of bacterial resistance to antimicrobial agents, a World Health Organization symposium. Clin Infect Dis 1997; 24: S1-176.
2. Cristina ML, Spagnolo AM, Orlando P, et al. The role of the environment in the spread of emerging pathogens in at-risk hospital wards. Rev Med Microbiol 2013; 24: 104-12.
3. Jevons MP, Coe AW, Parker MT. Methicillin resistance in staphylococci. Lancet 1963; 1: 904-7.
4. Manso E, Varaldo PE. La resistenza agli antibiotici negli stafilococchi. Website: Http: //www.masciabrunelli.it/biolife/upload/ file/Documenti/Documenta-imp-2002.PDF
5. Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults. Website: Http: //www.uptodate.com/contents/ epidemiology-of-methicillin-resistant-Staphylococcusaureus- infection-in-adults.
6. Kluytmans J, Struelens M. Meticillin resistant Staphylococcus aureus in the hospital. BMJ 2009; 338: B364.
7. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46: S344-9.
8. Gould IM, David MZ, Esposito S, et al. New insights into methicillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 2012; 39: 96-104.
9. Staphylococcus aureus. Website: Http: //www.iss.it/chem/index. php?lang=1& id=70& tipo=11.
10. Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin- intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010; 23: 99-139.
11. Tonin E, Tomasz A. Beta-lactam-specific resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1986; 30: 577-83.
12. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: A systematic review and meta-analysis. Clin Infect Dis 2012; 54: 755-71.
13. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
14. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.
15. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: A new model of antibiotic resistance. Lancet Infect Dis 2001; 1: 147-55.
16. van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55: 405-10.
17. van Hal SJ, Wehrhahn MC, Barbagiannakos T, et al. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol 2011; 49: 1489-94.
18. van Hal SJ, Jones M, Gosbell IB, et al. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin- resistant Staphylococcus aureus blood stream infections. PLoS One 2011; 6: E21217.
19. Saito M, Katayama Y, Hishinuma T, et al. "Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3. Antimicrob Agents Chemother 2014; 58: 5024-35.
20. Di Gregorio S, Perazzi B, Ordonez AM, et al. Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin- intermediate Staphylococcus aureus bacteremia in a teaching hospital. Microb Drug Resist 2015; 21: 25-34.
21. Hanaki H, Cui L, Ikeda-Dantsuji Y, et al. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011. J Infect Chemother 2014; 20: 527-34.
22. Chaudhari CN, Tandel K, Grover N, et al. Heterogeneous vancomycin- intermediate among methicillin resistant Staphylococcus aureus. Med J Armed Forces India 2015; 71: 15-8.
23. Monaco M, Sanchini A, Grundmann H, et al. Vancomycin-heteroresistant phenotype in invasive methicillin-resistant Staphylococcus aureus isolates belonging to spa type 041. Eur J Clin Microbiol Infect Dis 2010; 29: 771-7.
24. Renzoni A, Kelley WL, Vaudaux P, et al. Exploring innate glycopeptide resistance mechanisms in Staphylococcus aureus. Trends Microbiol 2010; 18: 55-6.
25. Rybak M, Chin JN, Lau K, et al. Increasing prevalence of glycopeptide hetero-resistant S. aureus from the Detroit metropolitan area over a 20-year period (1986-2006). In: 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and the 25th International Congress of Chemotherapy (ICC). 2007 [Abstract O32].
26. Appelbaum PC. MRSA-the tip of the iceberg. Clin Microbiol Infect 2006; 12: 3-10.
27. Blot SI, Vandewoude KH, Hoste EA, et al. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162: 2229-35.
28. Chang FY, MacDonald BB, Peacock Jr JE, et al. A prospective multicenter study of Staphylococcus aureus bacteremia: Incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore) 2003; 82: 322-32.
29. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin- resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-7.
30. Maor Y, Rahav G, Belausov N, et al. Prevalence and characteristics of heteroresistant vancomycin intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 2007; 45: 1511-4.
31. Kirby A, Graham R, Williams NJ, et al. Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK. J Antimicrob Chemother 2010; 65: 721-4.
32. Linares J. VISA/GISA problem: Therapeutic implications. Clin Microbiol Infect 2001; 7: 8-15.
33. Ottria G, Dallera M, Aresu O, et al. Environmental monitoring programme in the cell therapy facility of a research centre: Preliminary investigation. J Prev Med Hyg 2010; 51: 133-8.
34. Dietz B, Raht A, Wendt C, et al. Survival of MRSA on sterile goods packaging. J Hosp Infect 2001; 49: 255-61.
35. Centers for Disease Control and Prevention/Healthcare Infection Control Practices Advisory Committee (HICPAC). 2001. Draft Guidelines for Environmental Infection Control in Healthcare Facilities. Atlanta, GA: Centers for disease Control and Prevention. Available at www.cdc.gov/ncidod/hip/enviro/guide.htm.
36. Farr BM, Salgado CD, Karchmer TB, et al. Can antibiotic-resistant nosocomial infections be controlled? Lancet Infect Dis 2001; 1: 38-45.
37. Perdelli F, Dallera M, Cristina ML, et al. A new microbiological problem in intensive care units: Environmental contamination by MRSA with reduced susceptibility to glycopeptides. Int J Hyg Environ Health 2008; 211: 213-8.
38. Boccia D, D'Ancona F, Pantosti A. Resistenza alla Vancomicina in ceppi invasivi di Enterococcus faecalis ed enterococcus faecium. Dati preliminari Bollettino Epidemiologico Nazionale - Notiziario ISS -2002; 15(5).
39. Walsh T R, Howe R A, Wootton M, et al. Detection of glycopeptide resistance in Staphylococcus aureus. J Antimicrob Chemother 2001; 47: 357-8.
40. Ariza J, Pujol M, Cabo J, et al. Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet 1999; 353: 1587-8.
41. Moore M R, Perdreau-Remington F, Chambers HF. Vancomycin treatment failure associated with heterogeneous vancomycin- intermediate Staphylococcus aureus in patient with endocarditis and in the rabbit model of endocarditis. Antimicrob Agents Chemother 2003; 47: 1262-6.
42. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: E18-55.
43. Infection Prevention Working Party. MRSA Hospital. The Netherlands, 2007.
44. Rodriguez-Bano J, Bischofberger C, Alvarez-Lerma F, et al. Vigilancia y el control de Staphylococcus aureus resistente a meticilina en hospitales espanoles. Documento de consenso GEIH-SEIMC y SEMPSPH. Enferm Infecc Microbiol Clin 2008; 26: 285-98.
45. Calfee DP, Salgado CD, Classen D, et al. SHEA/IDSA. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect Control Hosp Epidemiol 2008; 29: 62-80.
46. Cystic Fibrosis Trust. Methicillin-resistant Staphylococcus aureus (MRSA). Report of the UK Cystic Fibrosis Trust Infection Control Working Group 2008.
47. Borgman S, Stark M, Kaiser P, et al. MRSA in praxis, pflegeheim und hauslichem umfeld. Bayerisches Arzteblatt 2008; 3: 176-81.
48. Tacconelli E. Screening and isolation for infection control. J Hosp Infect 2009; 73: 371-7.
49. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008; 299: 1149-57.
50. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008; 148: 409-18.
51. Jeyaratnam D, Whitty CJ, Phillips K, et al. Impact of rapid screening tests on acquisition of methicillin resistant Staphylococcus aureus: Cluster randomised crossover trial. BMJ 2008; 336: 927-30.
52. Raineri E, Crema L, De Silvestri A, et al. Methicillin-resistant Staphylococcus aureus control in an intensive care unit: A 10 year analysis. J Hosp Infect 2007; 67: 308-15.
53. Keshtgar MR, Khalili A, Coen PG, et al. Impact of rapid molecular screening for methicillin-resistant Staphylococcus aureus in surgical wards. Br J Surg 2008; 95: 381-6.
54. Tacconelli E, De Angelis G, de Waure C, et al. Rapid screening tests for methicillin-resistant Staphylococcus aureus at hospital admission: Systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 546-54.
55. van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 2008; 4: CD006216.
56. Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Weekly Rep 1997; 46: 626-35.
57. Wenzel RP, Edmond MB. Vancomycin-resistant Staphylococcus aureus: Infection control considerations. Clin Infect Dis 1998; 27: 245-51.
58. Kalenic S, Cookson B, Gallagher R, et al. Comparison of recommendations in national/regional Guidelines for the prevention and control of MRSA in thirteen European countries. Int J Infect Control 2010; v6: I2.
59. Spagnolo AM, Orlando P, Panatto D, et al. An overview of carbapenem- resistant Klebsiella pneumoniae: Epidemiology and control measures. Rev Med Microbiol 2014; 25: 7-14.
60. Cristina ML, Spagnolo AM, Cenderello N, et al. Multidrugresistant Acinetobacter baumannii outbreak: An investigation of the possible routes of transmission. Public Health 2013; 127: 386-91.
61. Cristina ML, Spagnolo AM, Ottria G, et al. Spread of multidrug carbapenem-resistant Acinetobacter baumannii in different wards of an Italian hospital. Am J Infect Control 2011; 39: 790-4.
62. Cristina ML, Spagnolo AM, Sartini M, et al. Clostridium difficile infections: An emerging problem in healthcare facilities. Rev Med Microbiol 2012; 23: 67-75.
63. Raccomandazioni sul controllo della diffusione nosocomiale dello Staphylococcus aureus resistente alla meticillina (MRSA) 2011. A cura di: Istituto Superiore di Sanita, Agenzia sanitaria e sociale regionale dell'Emilia-Romagna, Ministero della salute - Ufficio V Malattie infettive, Direzione generale della prevenzione sanitaria. Disponibile sul sito: Http: //asr.regione. emilia-romagna.it/wcm/asr/aree-di-programma/rischioinfettivo/ gr-ist/pr-staph/pubblicazioni/report-mrsa/link/mrsa.pdf.
64. Kapil R, Bhavsar HK, Madan M. Hand hygiene in reducing transient flora on the hands of healthcare workers: An educational intervention. Indian J Med Microbiol 2015; 33: 125-8.
65. Monistrol O, Lopez ML, Riera M, et al. Hand contamination during routine care in medical wards: The role of hand hygiene compliance. J Med Microbiol 2013; 62: 623-9.
66. Al-Tawfiq JA, Abed MS, Al-Yami N, et al. Promoting and sustaining a hospital-wide, multifaceted hand hygiene program resulted in significant reduction in health care-associated infections. Am J Infect Control 2013; 41: 482-6.
67. Sunkesula V, Kundrapu S, Macinga DR, et al. Efficacy of alcohol gel for removal of methicillin-resistant Staphylococcus aureus from hands of colonized patients. Infect Control Hosp Epidemiol 2015; 36: 229-31.
68. Hedin G, Blomkvist A, Janson M, Lindblom A. Occurrence of potentially pathogenic bacteria on the hands of hospital patients before and after the introduction of patient hand disinfection. APMIS 2012; 120: 802-7.
69. Orlando P, Cristina ML, Dallera M, et al. Surface disinfection: Evaluation of the efficacy of a nebulization system spraying hydrogen peroxide. J Prev Med Hyg 2008; 49: 116-9.
70. Gidengil CA, Gay C, Huang SS, et al. Cost-effectiveness of strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in an intensive care unit. Infect Control Hosp Epidemiol 2015; 36: 17-27.
71. Huang SS, Septimus E, Avery TR, et al. Cost savings of universal decolonization to prevent intensive care unit infection: Implications of the REDUCE MRSA trial. Infect Control Hosp Epidemiol 2014; 35(Suppl 3): S23-31.
72. Borde JP, Batin N, Rieg S, et al. Adherence to an antibiotic stewardship bundle targeting Staphylococcus aureus blood stream infections at a 200-bed community hospital. Infection 2014; 42: 713-9.
73. Cook PP, Gooch M. Long-term effects of an antimicrobial stewardship programme at a tertiary-care teaching hospital. Int J Antimicrob Agents 2015; 45: 262-7.
74. Pulcini C, Williams F, Molinari N, Davey P, Nathwani D. Junior doctors' knowledge and perceptions of antibiotic resistance and prescribing: A survey in France and Scotland. Clin Microbiol Infect 2011; 17: 80-7.
75. Chan YY, Lin TY, Huang CT, et al. Implementation and outcomes of a hospital-wide computerised antimicrobial stewardship programme in a large medical centre in Taiwan. Int J Antimicrob Agents 2011; 38: 486-92.